Viridian Therapeutics, Inc. (NASDAQ: VRDN) reported Q2 EPS of ($1.00), in-line with the analyst estimate of ($1.00). Revenue for the quarter came in at $75 thousand versus the consensus estimate of $50.92 thousand.

For earnings history and earnings-related data on Viridian Therapeutics, Inc. (VRDN) click here.